Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RESPECT-D Clear all
Completed Not applicable Interventional Results available

Acceptance-based Group Intervention for Binge Eating

NCT01757847
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Acceptance and Commitment Therapy (ACT), Brief MOVE-II control group intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

NCT01640093
View directory record Official record
Conditions
Healthy Participants
Interventions
Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet), Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

NCT01897389
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

NCT02220218
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02865668
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 6, 2026, 3:29 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Not applicable Interventional

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NCT02358694
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

NCT01411774
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, d-cycloserine, Pill placebo
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
St. Petersburg, Florida • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

NCT01855321
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02221180
View directory record Official record
Conditions
Bioequivalence
Interventions
Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02846506
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Not applicable Interventional

Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial

NCT01583400
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Minor, Dysthymic Disorder
Interventions
RESPECT-D, RESPECT-D-E (Enhanced)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Keene, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Not applicable Interventional

Exercise-based Motivational Interviewing for Fibromyalgia

NCT00573612
View directory record Official record
Conditions
Fibromyalgia
Interventions
Attention Control Counseling, Motivational Interviewing
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 6, 2026, 3:29 AM EDT
Not listed Phase 3 Interventional

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old

NCT03257241
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
A arm (DA-90), B arm (DAC), A arm (CLAG-M), B arm (FLAG-IDA)
Drug
Lead sponsor
Polish Adult Leukemia Group
Other
Eligibility
18 Years to 60 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 6, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

NCT02031666
View directory record Official record
Conditions
Healthy
Interventions
JNJ-56021927 capsule, JNJ-56021927 tablet
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Sep 6, 2026, 3:29 AM EDT